Investor Relations

KemPharm^® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Investor Relations

Change

Volume

52 Week High

52 Week Low

Feb 18, 2019 10:01 AM EST

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date	Title and Summary
Toggle SummarySeptember 16, 2009	KemPharm, Inc. Expands Prodrug Pipeline with Candidate for Treatment of Pain and Closes Series B Financing
Toggle SummaryOctober 22, 2009	KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
Toggle SummaryJanuary 11, 2010	KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP106 for ADHD
Toggle SummaryMay 18, 2010	KemPharm, Inc. Announces Entering Into an Exclusive Supply Agreement With Johnson Matthey Inc. for KP201

Investor Relations

Investor Relations

KemPharm uses its LAT^™ Technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

News Releases

Upoming Events

Investor Relations

Investor Relations

KemPharm uses its LAT™ Technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

News Releases

Upoming Events

KemPharm uses its LAT^™ Technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.